Cash, cash equivalents and restricted cash as of June 30, 2025 was $162.1 million and is expected to support planned operations, including completion of the ongoing Phase 3 AURORA trial for Descartes-08 in MG, into mid-2027.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNAC:
- Cartesian Therapeutics announces new employment inducement grants
- Cartesian Therapeutics Advances mRNA CAR T-cell Therapy for Myasthenia Gravis
- Wedbush bullish on Cartesian Therapeutics, initiates with an Outperform
- Cartesian Therapeutics initiated with an Outperform at Wedbush
- Cartesian Therapeutics Holds Annual Stockholders Meeting